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Abstract 
Background: Cognitive impairments are well-established features of schizophrenia 
whereas there is ongoing debate about nature and degree of cognitive performance 
in schizoaffective disorder and bipolar disorder. We hypothesised that there is a 
spectrum of increasing impairment from bipolar disorder to schizoaffective-bipolar 
type to schizoaffective-depressive type and schizophrenia. 
Method: Performance on the MATRICS Consensus Cognitive Battery was compared 
between participants with schizophrenia (N=558), schizoaffective-depressive type 
(N=112), schizoaffective-bipolar type (N=76), bipolar disorder (N=78) and healthy 
participants (N=103) using analysis of covariance with post-hoc comparisons. An 
ordinal logistic regression was conducted to examine whether cognitive impairments 
followed the hypothesised spectrum from bipolar disorder (least severe) to 
schizophrenia (most severe). In addition to categorical diagnoses we addressed the 
influence of symptom domains, examining the association between cognition and 
mania, depression and psychosis.  
Results: Cognitive impairments increased in severity from bipolar disorder to 
schizoaffective-bipolar to schizophrenia/schizoaffective-depressive. Participants with 
schizophrenia and schizoaffective-depressive displayed equivalent performance 
(d=0.07,p=0.90). The results of the ordinal logistic regression were consistent with a 
spectrum of deficits from bipolar disorder to schizoaffective-bipolar type to 
schizophrenia/schizoaffective-depressive type (OR=1.98, p=2.4x10-16). In analyses of 
the associations between symptom dimensions and cognition, higher scores on the 
psychosis dimension were associated with poorer performance (B=0.015
p=3.2 x 10-16).  
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Limitations: There were fewer participants with schizoaffective disorder and bipolar 
disorder than schizophrenia. Despite this, our analyses were robust to differences in 
the group sizes and we were able to detect differences between groups. 
Conclusion: Cognitive impairments represent a symptom dimension that cuts across 
traditional diagnostic boundaries. 
Declaration of interest: None.  
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Introduction 1 
Current diagnostic approaches view schizophrenia and bipolar disorder as distinct 2 
psychiatric conditions, despite emerging evidence of significant genetic and 3 
phenotypic overlap between the disorders 1. One of the most obvious challenges to 4 
the simple dichotomous view is the existence of the intermediate condition, 5 
schizoaffective disorder 2. The relationship between schizoaffective disorder and 6 
schizophrenia and bipolar disorder is uncertain and it has been variously suggested 7 
that schizoaffective disorder is a sub-type of either schizophrenia or bipolar disorder, 8 
that it reflects comorbidity of schizophrenia and mood disorder, that it is an 9 
independent disorder, and, finally, that it lies in the middle of a spectrum that ranges 10 
from a predominantly affective disorder to a predominantly psychotic disorder 3. The 11 
latter hypothesis suggests that prototypical bipolar disorder and schizophrenia lie on 12 
the extreme ends of a diagnostic spectrum with schizoaffective disorder 13 
representing patients who have features of both disorders 4. Support for this comes 14 
from evidence that symptomatic and functional outcomes for schizoaffective 15 
disorder are intermediate between schizophrenia and bipolar disorder 5, 6. More 16 
recently it has been proposed that schizophrenia and bipolar disorder lie on a 17 
gradient of neurodevelopmental impairment indexed by the extent of cognitive 18 
dysfunction, with schizoaffective disorders occupying an intermediate position 1, 7, 8. 19 
Neuropsychological studies that provide support for a diagnostic spectrum have 20 
demonstrated increasing severity of impairment from bipolar disorder to 21 
schizoaffective disorder to schizophrenia, although these differences were not 22 
always significant 9-11. In one of the largest studies to date, Hill et al. 10 showed an 23 
association between ratings on the Schizo-Bipolar scale 12 and composite cognition 24 
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scores with more severe impairments amongst those with prominent psychosis and 25 
fewer affective symptoms. However, findings from neuropsychological studies of 26 
these three disorders have been inconsistent with some studies indicating that 27 
performance in schizoaffective disorder is similar to schizophrenia 13 and others 28 
indicating no differences between diagnostic groups 14-17.  29 
There are a number of potential explanations for the conflicting findings between 30 
studies including differences in the use of covariates and the phase of illness of the 31 
study participants. Studies of symptomatic participants with schizophrenia, 32 
schizoaffective disorder and bipolar disorder have reported similar levels of 33 
impairment 15, 16. It has been argued that cognitive impairments are state dependent 34 
in bipolar disorder and therefore improve during periods of remission. However, 35 
more recent research has demonstrated that cognitive impairments are present in 36 
euthymic bipolar disorder 18. Lifetime history of psychosis in bipolar disorder has 37 
been identified as another important factor that may influence cognitive function. 38 
Studies do not consistently report the proportion of participants with bipolar 39 
disorder who have a lifetime history of psychosis despite evidence that the presence 40 
or absence of lifetime psychosis differentiates participants with cognitive 41 
impairments from those without impairments 17. Finally, studies often consider 42 
schizoaffective disorder as a single group but there is little data to indicate whether 43 
differences exist between the subtypes of schizoaffective disorder (depressive or 44 
bipolar). The study by Hill et al. 10 showed greater overall impairment in participants 45 
with the depressive subtype of schizoaffective disorder than the bipolar subtype, 46 
although the differences were not significant. Two smaller studies found no 47 
differences between participants with the depressive subtype and participants with 48 
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schizophrenia but did not consider the bipolar subtype 14, 19. This suggests 49 
amalgamation of both subtype of schizoaffective disorder as a single group may 50 
obscure findings. To our knowledge, there have been no published studies that have 51 
compared the subtypes of schizoaffective disorder individually to schizophrenia and 52 
bipolar disorder.  53 
The aim of this study was to test the hypothesis that there is a spectrum of 54 
increasing cognitive impairment from bipolar disorder through schizoaffective 55 
bipolar to schizoaffective depressive and schizophrenia. We also hypothesised that 56 
lifetime frequency and severity of psychotic symptoms (across and within diagnostic 57 
boundaries) would be associated with cognitive impairment. These hypotheses were 58 
tested in three ways. Firstly, we compared cognitive performance between the 59 
diagnostic groups. Secondly, we examined whether cognition can be considered a 60 
continuous measure across disorders. For this analysis, the schizophrenia and 61 
schizoaffective depressive groups were combined into a single group based on pre-62 
existing data suggesting that performance between these groups is equivalent10, 14, 63 
19. Thirdly, we examined whether cognitive performance is associated with 64 
symptoms domains across diagnostic groups.  65 
Methods 66 
 67 
Participants 68 
Participants were recruited as part of the Cognition in Mood, Psychosis and 69 
Schizophrenia Study (COMPASS), a UK based study that recruits from outpatient 70 
clinics. This sample includes participants previously referred to as the Cardiff 71 
Cognition in Schizophrenia (COGS) sample (described elsewhere in 20). All patient 72 
groups were recruited as part of a single study and all aspects of recruitment, 73 
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response rates, phenotyping and determining diagnosis were equivalent across 74 
groups. Participants were interviewed using the Schedules for Clinical Assessment in 75 
Neuropsychiatry (SCAN) 21. This interview was reviewed along with available clinical 76 
records by trained raters to determine a consensus lifetime DSM-IV diagnosis22 77 
(inter-rater reliability Kappa statistics: schizophrenia=0.83, schizoaffective 78 
depressive=0.63, schizoaffective bipolar=0.72, bipolar disorder=0.85). The final 79 
sample included 824 participants with a diagnosis of schizophrenia (N=558), 80 
schizoaffective depressive (N=112), schizoaffective bipolar (N=76) or bipolar disorder 81 
(N=78). The bipolar disorder group included all participants who met criteria for a 82 
diagnosis of bipolar disorder – type I (N=68) or type II (N=10), of which 59 had a 83 
lifetime history of psychosis. Participants were excluded if they suffered from a 84 
neurological condition that was likely to impact their ability to participate in the 85 
study or had a current substance dependence disorder.  86 
One hundred and three control participants were recruited from the community and 87 
completed the Mini International Neuropsychiatric Interview (MINI) 23 as a screen 88 
for mental disorders. Controls were excluded if they met criteria for schizophrenia or 89 
bipolar disorder or there was a family history of these conditions. All participants 90 
provided written informed consent and were reimbursed for their participation. 91 
Participants were assessed for capacity to provide informed consent by their clinical 92 
team and an appropriately trained researcher. The study had UK multi-site NHS 93 
ethics approval.  94 
Neuropsychological Assessment 95 
Cognitive ability was assessed using the Measurement and Treatment Research to 96 
Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery 97 
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(MCCB24). This battery was designed specifically for use in schizophrenia research 98 
but has been shown to be a valid and reliable cognitive measure in bipolar disorder 99 
25-27.  The MCCB measures seven domains of cognition using ten tasks:  100 
1. Speed of processing (Brief Assessment of Cognition in Schizophrenia: Symbol 101 
Coding; Category Fluency: Animal Naming; Trail Making Test: Part A)  102 
2. Working memory (Wechsler Memory Scale III: Spatial Span; Letter-Number 103 
Span) 104 
3. Attention / vigilance (Continuous Performance Test: Identical Pairs) 105 
4. Verbal learning (Hopkins Verbal Learning Test-Revised) 106 
5. Visual learning (Brief Visuospatial Memory Test-Revised) 107 
6. Reasoning and problem solving (Neuropsychological Assessment Battery: 108 
Mazes)  109 
7. Social cognition (Mayer-Salovey-Caruso Emotional Intelligence Test: 110 
Managing Emotions).  111 
For each task, z scores were derived using the mean and standard deviation of the 112 
control group (50% males, mean age = 41.7 years). Domain and composite scores 113 
were calculated following the MCCB manual procedures. Composite scores were 114 
only calculated if a participant had completed 5 or more domains. It was possible to 115 
calculate composite scores for 926 of the 927 participants. 116 
Clinical and Demographic Variables 117 
Lifetime mood and psychosis was rated using the Bipolar Affective Disorder 118 
Dimension Scale (BADDS28). The BADDS comprises of four dimensions, Mania, 119 
Depression, Psychosis and Incongruence. The first three dimensions were included 120 
and reflect the severity and frequency of these symptom domains. Current 121 
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symptoms were rated as the total of the global scores for the Scale for the 122 
Assessment of Negative Symptoms (SANS29) and the Scale for the Assessment of 123 
Positive Symptoms (SAPS30). Global functioning was measured using the Global 124 
Assessment Scale (GAS31). Premorbid IQ was estimated using the National Adult 125 
Reading Test.32 Doses of antipsychotic medication at time of assessment were 126 
calculated as olanzapine equivalents33 and lifetime antipsychotic exposure was 127 
calculated from interview and notes data in number of months. Intraclass correlation 128 
coefficients for the clinical variables ranged from 0.71 to 0.95.   129 
Analysis 130 
Comparing cognition between diagnostic groups 131 
Statistical analyses to compare the groups were performed using R version 3.1.2. For 132 
each cognitive domain and across diagnostic groups, performance was compared 133 
using analysis of covariance with age and sex as covariates and followed up with 134 
Tukey’s H“D for pairǁise ĐoŵparisoŶs. BoŶferroŶi ĐorreĐtioŶ ǁas used to adjust for 135 
multiple comparisons resulting in an alpha of 0.00625 (0.05/8, 7 domains and 136 
composite score). The alpha was not corrected further for the number of pairwise 137 
ĐoŵparisoŶs, as Tukey’s H“D is already a ĐoŶserǀatiǀe test that ĐorreĐts for faŵily-138 
ǁise error rate. CoheŶ’s d ǁere ĐalĐulated ďy diǀidiŶg ŵeaŶ group differeŶĐe ďy the 139 
pooled standard deviation and used as a measure of effect size.34 Repeated 140 
measures analysis of variance was used to compare profiles of cognitive 141 
performance between groups. The within-subject factor was cognitive domain. The 142 
effects of medication and symptoms as potential confounding variables were 143 
investigated by including olanzapine equivalent dose, duration of antipsychotic 144 
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exposure, SAPS total scores, SANS total scores, BADDS lifetime depression, 145 
educational attainment and parental occupation as covariates. 146 
Examining cognition as a dimension across diagnostic groups 147 
To test our hypothesis that cognition can be considered a dimensional phenotype 148 
showing increasing impairment from bipolar disorder to schizoaffective bipolar to 149 
schizophrenia and schizoaffective depressive combined, we conducted an ordinal 150 
regression using SPSSv.22 with diagnosis as the outcome, composite cognition score 151 
as the predictor and age and sex as covariates. Schizophrenia and schizoaffective 152 
depressive were combined given pre-existing data indicating that their degree of 153 
impairment is comparable 10, 14, 19. Diagnosis was coded on an ordinal scale 154 
combining schizoaffective depressive and schizophrenia: 0 – schizoaffective 155 
depressive and schizophrenia, 1 – schizoaffective bipolar, 2 – bipolar disorder.  156 
Cross disorder symptom dimensions and cognitive performance 157 
Finally, each BADDS dimension was entered into separate linear regressions as 158 
predictors with composite cognition as the outcome using R version 3.1.2. This was 159 
initially done across the whole sample and then separately for bipolar disorder / 160 
schizoaffective bipolar and schizophrenia / schizoaffective depressive.  161 
Results 162 
 163 
Demographic and clinical variables 164 
Demographic and clinical variables are displayed for each diagnostic group in Table 165 
1. Groups differed in proportion of males (χ2=61.39, p<0.001) with more males 166 
observed in the schizophrenia group therefore sex was used as a covariate in all 167 
analyses. There were differences in estimated premorbid IQ (F=22.64, p<0.001) and 168 
years in education (F=14.19, p<0.001), which were lower for those with 169 
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schizophrenia and schizoaffective depressive compared to those with bipolar 170 
disorder and schizoaffective bipolar. Groups differed on current positive and 171 
negative symptoms (SAPS: F=65.96, p=3.13 x 10-14; SANS: F=64.16, p=7.58 x 10-14) 172 
with lower scores in those with bipolar disorder compared to all other groups. 173 
Measures of current global functioning (Global Assessment Scale) differed between 174 
groups (F=4.99, p=0.002) with higher scores observed in the bipolar disorder group. 175 
Comparing cognition between diagnostic groups 176 
There was a significant main effect of diagnosis for all domains of cognition in the 177 
analysis of covariance (for example, composite cognition: F(4, 921) = 94.12, 178 
p<0.00625, see supplementary table S1 for full results). Figure 1 displays the z scores 179 
(marginal means) observed for each group demonstrating an increasing severity of 180 
cognitive impairments from controls to bipolar disorder to schizoaffective bipolar to 181 
schizophrenia and schizoaffective depressive. 182 
Effect sizes for each pairwise comparison between diagnoses for all domains are 183 
displayed in Figure 2. All diagnostic groups were impaired compared to controls 184 
across cognitive domains with the exception of social cognition in those with bipolar 185 
disorder. The bipolar disorder group was the least impaired of the diagnostic groups, 186 
performing 0.5 to 1.25 standard deviations below the mean of the control group 187 
across domains (composite cognition: d=1.12, p<0.001). Although the groups were 188 
small, we compared bipolar disorder – type I (N=68) and bipolar disorder – type II 189 
(N=10) and found no significant differences between these groups (composite 190 
cognition: d=-0.07, p=0.83, see supplementary table S2 for comparisons between 191 
domains). The results remained consistent when the analysis was restricted to 192 
bipolar disorder – type I (see supplementary table S3). We also compared bipolar 193 
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disorder with and without psychosis and found no significant differences between 194 
these groups (composite cognition: d=0.34, p=0.2, see supplementary table S4 for 195 
comparisons between domains). We note that caution should be applied in the 196 
interpretation of the results comparing subgroups of bipolar disorder given the small 197 
sample of participants without psychosis (N=19) and with bipolar disorder – type II 198 
(N=10). The schizoaffective bipolar group was more impaired than the bipolar 199 
disorder group although this does not withstand correction for multiple testing 200 
(composite cognition: d=0.44, p=0.02). The schizophrenia and schizoaffective 201 
depressive groups were the most cognitively impaired and did not differ on any 202 
cognitive variable (composite cognition: d=0.07, p=0.90) corroborating our a priori 203 
decision to amalgamate these groups for subsequent analyses. These participants 204 
were more impaired than those with schizoaffective bipolar (schizophrenia: d=0.52, 205 
p<0.001; schizoaffective depressive: d=0.45, p=0.01) and those with bipolar disorder 206 
(schizophrenia: d=0.90, p<0.001; schizoaffective depressive: d=0.83,p<0.001). In 207 
contrast to other domains, levels of impairment in social cognition between 208 
schizoaffective bipolar, schizoaffective depressive and schizophrenia did not differ 209 
;CoheŶ’s d for pairǁise ĐoŵparisoŶs ďetǁeeŶ these groups raŶged ďetǁeeŶ Ϭ.Ϭ5 210 
and 0.28). All three of these groups were more impaired than bipolar disorder on 211 
soĐial ĐogŶitioŶ ;CoheŶ’s d raŶged ďetǁeeŶ Ϭ.5Ϭ aŶd Ϭ.ϴϭͿ. 212 
In order to test whether between group differences were qualitative or merely 213 
quantitative we compared cognitive profiles between diagnostic groups using 214 
repeated measures analysis of variance, with cognitive domain included as the 215 
within-subject factor. MauĐhly’s test iŶdiĐated that the assuŵptioŶ of spheriĐity had 216 
been violated (χ2(20)=360.23, p=3.5 x 10-64) therefore degrees of freedom were 217 
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corrected using Huynh-Feldt  estimates of sphericity. The diagnosis-by-domain 218 
interaction was not significant (F=1.62, df=15.50, 3051.33, p=0.06). The analysis was 219 
repeated excluding social cognition (given the quantitative differences in this 220 
domain) and the diagnosis-by-domain interaction was not significant (F=1.604, 221 
df=1.60, 2680.70 p=0.07) indicating that patterns of cognitive ability did not differ by 222 
diagnostic group but rather differed quantitatively. 223 
We went on to investigate the effects of the potential confounding variables: 224 
olanzapine equivalent dose, duration of antipsychotic exposure, total SANS scores 225 
and total SAPS scores. The main effect of diagnostic group on composite cognitive 226 
scores remained significant after controlling for duration of antipsychotic exposure 227 
(F(3,765)=16.18, p=3.4 x 10-10), olanzapine equivalent dose at time of testing 228 
(F(3,773)=21.42, p=2.5 x 10-13), total SAPS score (F(3,807)=24.52, p=3.4 x 10-15) and 229 
total SANS score (F(3,805)=16.71, p=1.6 x 10-10, see supplementary tables S5-S8 for 230 
full data). Olanzapine equivalent dose at time of testing, duration of antipsychotic 231 
exposure and negative symptoms were associated with cognitive performance on all 232 
domains. Current psychotic symptoms (SAPS score) were not associated with 233 
performance across domains, other than social cognition. The analyses were also 234 
repeated including educational attainment and parental occupations (as measures of 235 
socioeconomic status) and the effect of diagnosis on cognition remained significant 236 
(supplementary table S9). Finally, diagnosis, olanzapine equivalent dose, duration of 237 
antipsychotic exposure, total SANS scores, total SAPS scores and lifetime depression 238 
(as measured by the BADDS depression scale) were added as predictors into a single 239 
model. The main effect of diagnostic group on composite cognition remained 240 
significant (F(3,694)=8.33, p=1.9 x 10-5, see supplementary table S10 for individual 241 
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domains). After correction for multiple testing, there were significant differences in 242 
composite cognition scores between schizoaffective depressive and bipolar disorder 243 
(d=0.65, p<0.001) and schizophrenia and bipolar disorder (d=0.58, p<0.001). The 244 
relative contributions of each covariate can be found in supplementary table S11. 245 
Examining cognition as a dimension across diagnostic groups 246 
We used ordinal regression to test whether cognition can be considered a 247 
dimensional phenotype across the diagnostic spectrum. This analysis indicated that 248 
higher cognitive scores were associated with higher scores on the diagnostic scale 249 
(0=schizoaffective depressive / schizophrenia, 1=schizoaffective bipolar and 250 
2=bipolar disorder, see supplementary table S12 for full model) supporting a 251 
spectrum of increasing impairment from bipolar disorder to schizoaffective bipolar 252 
to schizophrenia/schizoaffective depressive. An alternative way of interpreting this 253 
result is that among our clinical cases participants with a one standard deviation 254 
higher score in composite cognition were almost twice as likely to be diagnosed with 255 
schizoaffective bipolar or bipolar disorder compared to schizophrenia (OR = 1.98, p = 256 
2.4 x 10-16). Ordinal regression outputs a single odds ratio for the effect of the 257 
explanatory variable across all levels of the dependent variable because there is an 258 
assumption that the coefficients must be equal across all levels (assumption of 259 
proportional odds). This assumption was confirmed using the test of parallel lines in 260 
SPSS (χ2=4.97, df=3, p=0.17) and by comparing the coefficients for binary regressions 261 
for each cut-off point in the scale. The results of the ordinal regression did not 262 
change after adjustment for olanzapine equivalent dose, antipsychotic exposure in 263 
months and current negative symptoms (OR = 1.63, p = 4.9 x 10-7), although we 264 
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interpret this result with caution given the proportional odds assumption was 265 
violated in this model (χ2=26.98, p=1.5 x 10-4). 266 
The analysis was followed up with binary regressions between the diagnostic groups 267 
(model 1: bipolar disorder and schizoaffective bipolar; model 2: schizoaffective 268 
bipolar and schizoaffective depressive/schizophrenia) to compare the gradients from 269 
one diagnosis to the next on the scale (see supplementary table S12). The resulting 270 
coefficients were equivalent for models 1 and 2. This confirmed that there is a 271 
gradient of increasing impairment from bipolar disorder to schizoaffective bipolar to 272 
schizophrenia / schizoaffective depressive. 273 
Cross disorder symptom dimensions and cognitive performance 274 
Median BADDS dimension scores for each diagnostic group are presented in 275 
supplementary table S13. Higher scores on the lifetime mania and depression 276 
dimensions were associated with better cognitive performance (mania: B=0.010, 277 
SE=0.001, p=6.4 x 10-13; depression: B=0.004, SE=0.001, p=.012). Higher scores on 278 
the lifetime psychosis dimension predicted poorer cognitive performance (psychosis: 279 
B=-0.015, SE=0.002, p=3.2 x 10-16). In the subgroup analyses (bipolar disorder and 280 
schizoaffective bipolar only, schizophrenia and schizoaffective depressive only), 281 
neither mania nor depression scores predicted performance but higher psychosis 282 
scores were associated with lower cognitive scores (schizoaffective bipolar / bipolar 283 
disorder: B=-0.010, SE=0.003, p=0.0006; schizoaffective depressive / schizophrenia: 284 
B=-0.011, SE=0.003, p=0.0009). All analyses were repeated adjusting for age, sex, 285 
antipsychotic exposure in months, olanzapine equivalent dose and current negative 286 
symptoms. This did not change the results (see supplementary table S14), although 287 
the association between BADDS psychosis scores and cognition in the schizoaffective 288 
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depressive and schizophrenia subgroup did not survive correction for multiple 289 
testing.  290 
Discussion 291 
We set out to test the hypothesis that there is a spectrum of increasing cognitive 292 
impairment from bipolar disorder to schizophrenia and schizoaffective depressive. 293 
We report that whilst cognitive profiles were similar across disorders, these 294 
impairments increased in severity from bipolar disorder to schizoaffective bipolar to 295 
schizophrenia and schizoaffective depressive. There were no differences between 296 
schizophrenia and schizoaffective depressive in severity of cognitive impairments. 297 
Differences between the groups were not explained by differences in antipsychotic 298 
medication or current positive and negative symptoms. In accordance with our 299 
hypothesis, ordinal regression modelling provided support for a gradient of 300 
increasing cognitive impairment across disorders. Finally we found that higher scores 301 
on the BADDS psychosis dimension, a measure of the severity and frequency of 302 
lifetime psychosis, were associated with lower cognitive scores. 303 
Performance across the cognitive domains was equivalent in the schizophrenia and 304 
schizoaffective depressive groups. These results suggest that from a cognitive 305 
perspective, there is questionable validity in the nosological distinction between 306 
schizophrenia and schizoaffective depressive. Therapies developed to improve 307 
cognition in schizophrenia should also be targeted towards patients with 308 
schizoaffective depressive type. These findings also highlight the importance of 309 
considering the subtypes of schizoaffective disorder separately, as these groups 310 
differed in severity of cognitive impairments.  311 
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Differences in overall cognition between schizoaffective bipolar and bipolar disorder 312 
were not significant after correction for multiple testing. However, the effect size 313 
between these groups (d=0.44) was larger than that observed between 314 
schizophrenia and schizoaffective depressive (d=0.07). This may explain why a linear 315 
trend from bipolar disorder to schizoaffective bipolar to schizophrenia and 316 
schizoaffective depressive was still observed in the ordinal regression analysis. We 317 
used a conservative Bonferroni-corrected alpha value to control the type-I error rate 318 
but at the cost of loss of power, which could explain the lack of significant 319 
difference. However, it should be noted that there were smaller differences between 320 
schizoaffective bipolar and bipolar disorder on individual domains, which were not 321 
significant even at alpha=0.05.  322 
Diagnostic groups were differentiated on the basis of severity of cognitive 323 
impairments but the overall pattern of impairment was similar between the groups 324 
(Fig. 1). This suggests cognitive impairment can be considered a dimensional 325 
phenotype that cuts across diagnostic boundaries. These results are consistent with 326 
the results of previous studies showing that multiple domains of cognition are 327 
affected and these impairments increase in severity from bipolar disorder to 328 
schizophrenia 9-12. Similarities between the cognitive profiles of these disorders are 329 
consistent with a shared underlying neurobiology that differs quantitatively rather 330 
than qualitatively across the diagnostic groups 1, 7, 8. Indeed, previous studies have 331 
indicated overlap in regions of grey matter reduction (though less consistently in 332 
bipolar disorder) 35-38 and genetic susceptibility 39-42. 333 
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Whilst neurocognitive impairments were evident across all diagnoses, impairments 334 
in social cognition were not present in bipolar disorder but were observed in 335 
schizophrenia and schizoaffective disorder. The largest difference between 336 
participants with schizoaffective bipolar and bipolar disorder was observed in social 337 
cognition suggesting there may be some distinction in the cognitive processes 338 
underlying these disorders despite similar neurocognitive profiles. Social cognition 339 
was the only domain associated with current positive symptoms. Previous studies 340 
have demonstrated associations between domains of social cognition, particularly 341 
theory of mind deficits, and psychotic symptoms in schizophrenia 43-45. These results 342 
suggest that certain social cognitive tasks may differentiate bipolar disorder from 343 
other disorders within the bipolar disorder / schizophrenia spectrum. The 344 
association between social cognitive impairment and psychosis provides support for 345 
cognitive models of psychosis that posit a role for social interpretations in the 346 
development of psychotic thinking 46.  347 
Lifetime history of psychosis, as measured by the BADDS psychosis dimension, was 348 
associated with cognitive performance in our cross-diagnostic analysis. The BADDS 349 
psychosis dimension measures the prominence of psychotic symptoms over the 350 
course of illness and considers both duration and number of psychotic episodes. 351 
Lifetime history of psychosis has been shown to be associated with poorer 352 
cognition17. Our results expand on these findings by using a dimensional approach to 353 
show that lifetime frequency and severity of psychosis predicts severity of cognitive 354 
impairments.  355 
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This study has several strengths. It is one of the largest samples to date and is of a 356 
sufficient size to allow us to separate the subtypes of schizoaffective disorder. The 357 
sample is well characterised with consensus lifetime diagnoses based on semi-358 
structured interview and medical records. The clinical characterisation of the sample 359 
allowed us to adjust for the effects of current symptoms and antipsychotic 360 
medication, including both current and lifetime antipsychotic exposure.   361 
Limitations 362 
A number of limitations should be noted. The sizes of the diagnostic groups were 363 
uneven and there was a larger sample of participants with schizophrenia than the 364 
other disorders. Despite this, our analyses were robust to differences in the group 365 
sizes and we were able to detect differences between groups. Our bipolar disorder 366 
group consisted of a mixture of patients with and without a lifetime history of 367 
psychosis. Given the small number of participants without psychosis, it was not 368 
possible to separate the bipolar group into those with and without history of 369 
psychosis to examine differences between these groups and schizophrenia or 370 
schizoaffective disorder. The MCCB was designed for use with participants with 371 
schizophrenia. Previous studies of bipolar disorder have failed to find deficits in 372 
executive functioning using the NAB Mazes task 25, 27, 47. The authors of these studies 373 
note that more complex measures of executive function, such as the Wisconsin Card 374 
Sorting Task, may be more sensitive to detecting deficits in bipolar disorder. 375 
Although our bipolar group was impaired on the NAB Mazes relative to controls, this 376 
task may not have been sufficiently complex to differentiate bipolar disorder and 377 
schizoaffective disorder – bipolar type. Furthermore, our bipolar group was not 378 
impaired on the social cognition task (MSCEIT) but previous studies have identified 379 
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deficits in theory of mind and emotion recognition suggesting that patients with 380 
bipolar disorder do have impairments in specific domains of social cognition 48, 49.  381 
Conclusion 382 
Using a large and well-characterised sample, we have demonstrated that there is a 383 
gradient of increasing cognitive impairment from bipolar disorder to schizoaffective 384 
bipolar to schizophrenia and schizoaffective depressive. Differences in cognitive 385 
profiles between the diagnoses were quantitative rather than qualitative. Our 386 
findings comparing cognition between diagnostic groups confirmed our a priori 387 
decision to combine participants with schizophrenia and schizoaffective depressive 388 
in the subsequent analyses. This argues against separating schizophrenia and 389 
schizoaffective depressive for such analyses. This study was also the first to use a 390 
regression model to demonstrate a gradient of cognitive impairment and show that 391 
a dimensional measure of lifetime psychotic episodes is linearly associated with 392 
cognition. These results provide support for a model of psychotic and affective 393 
disorders where diagnostic criteria focus on dimensional measures of symptoms 394 
rather than traditional diagnostic categories. 395 
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Tables 
Table 1 Demographic and Clinical Variables 
DSM-IV Diagnosis 
Bipolar 
Disorder 
Schizoaffective 
Disorder – 
Bipolar Type 
Schizoaffective 
Disorder – 
Depressive Type 
Schizophrenia  
N 78 76 112 558 
Age* 45.8 (10.6) 43.8 (10.6) 44.1 (10.1) 43.3 (11.9) 
Gender (% males) 40 46 40 69 
Estimated 
Premorbid IQ* 
97.5 (22.4) 94.0 (21.5) 85.3 (20.2) 81.7 (23.7) 
Years in Education* 14.6 (3.3) 13.7 (3.0) 12.3 (2.3) 12.7 (2.7) 
Taking 
Antipsychotic (%) 
63.2 74.7 77.7 85.5 
Olanzapine 
Equivalent Dose† 
8 (12) 15 (10) 15 (13.5) 13.7 (13.7) 
Antipsychotic 
exposure in 
months† 
60 (102) 153 (181.5) 168 (164.5) 170 (168) 
Current SAPS†§ 0 (0) 2 (5) 2 (5) 3 (6) 
Current SANS†§ 0.5 (3) 4 (5) 6 (7) 5.5 (7) 
GAS Past Week* 70.8 (14.2) 60.1 (16.8) 58.6 (15.8) 60.2 (15.1) 
SAPS: Scale for the Assessment of Positive Symptoms; SANS: Scale for the Assessment of Negative Symptoms; 
GAS: Global Assessment Scale 
*Means and standard deviations are presented. 
†Medians and interquartile ranges are presented due to non-normal distribution. 
§Current SAPS and SANS scores represent the sum of the global scores. 
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Figure Legends 
Figure 1: Neuropsychological performance for participants with bipolar disorder, 
schizoaffective bipolar, schizoaffective depressive and schizophrenia 
Figure 2: Pairwise comparisons. Footnote: Each 3x3 section displays the CoheŶ’s d 
effect sizes for the difference between two diagnostic groups for each domain of 
cognition. Lighter shade p<0.05, darker shade p<0.00625 
 
